Wilson Therapeutics is a privately-held biopharmaceutical company focused on improving the lives of patients with Wilson's disease through development of new treatment options and support for increased awareness and education about Wilson's disease. The Company's lead product candidate, WTX101, is currently in clinical development as a treatment for Wilson's disease, a rare genetic disease that affects approximately 1 in 15,000 people worldwide. Wilson Therapeutics was founded by HealthCap, one of the largest venture capital firms in Europe specialized in life sciences.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/16/14 | $40,000,000 | Series B |
Abingworth HealthCap MVM Partners | undisclosed |
